Checkmate-141, 2016 trial summary

A randomised clinical trial investigating the effect of nivolumab versus standard treatment in patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy

Studied treatment	nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks
Control treatment	standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab).

Patients	patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy
Size	361

Blindness	open-label	Inclusion period
Follow-up duration		Centers
Lost to FU		geographical localisation
Primary endpoint	overall survival	Design	Parallel groups

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-1867 [PMID: 27718784] link to pdf add to Mendeley

ClinicalTrial.gov record NCT02105636

Registering number	NCT02105636 (see trial on clinicaltrials.gov)
Code Name